Published in Cytometry on March 01, 1997
Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol (1999) 3.18
Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br J Pharmacol (2010) 1.24
An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett (2015) 1.05
Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer (1998) 0.80
Up regulation of Bax and down regulation of Bcl2 during 3-NC mediated apoptosis in human cancer cells. Cancer Cell Int (2015) 0.78
Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone (2004) 5.27
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer (2001) 4.49
Polymyositis: an overdiagnosed entity. Neurology (2003) 4.36
The macrophage in the persistence and pathogenesis of HIV infection. AIDS (1989) 4.06
J-shaped relation between change in diastolic blood pressure and progression of aortic atherosclerosis. Lancet (1994) 3.95
Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst (1997) 2.83
Bone density in non-insulin-dependent diabetes mellitus. The Rotterdam Study. Ann Intern Med (1995) 2.70
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res (2001) 2.64
Relation of alleles of the collagen type Ialpha1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women. N Engl J Med (1998) 2.64
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol (2001) 2.52
A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab (1998) 2.45
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol (1997) 2.29
Isolation of infectious C-type oncornavirus from human leukaemic bone marrow cells. Nature (1975) 2.22
The two acetyl-coenzyme A synthetases of Saccharomyces cerevisiae differ with respect to kinetic properties and transcriptional regulation. J Biol Chem (1996) 2.06
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res (1999) 2.06
Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet (1992) 1.92
Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer (1997) 1.88
Autogenous radial-cephalic or prosthetic brachial-antecubital forearm loop AVF in patients with compromised vessels? A randomized, multicenter study of the patency of primary hemodialysis access. J Vasc Surg (2005) 1.71
Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ (1997) 1.71
CCR5 genotype and resistance to vertical transmission of HIV-1. J Acquir Immune Defic Syndr (1999) 1.67
Normal or early development of puberty despite gonadal damage in children treated for acute lymphoblastic leukemia. N Engl J Med (1989) 1.67
Estrogen receptor polymorphism predicts the onset of natural and surgical menopause. J Clin Endocrinol Metab (1999) 1.67
Minimizing DNA recombination during long RT-PCR. J Virol Methods (1998) 1.62
Human immunodeficiency virus type 1 in spinal cords of acquired immunodeficiency syndrome patients with myelopathy: expression and replication in macrophages. Proc Natl Acad Sci U S A (1989) 1.61
A large-scale population-based study of the association of vitamin D receptor gene polymorphisms with bone mineral density. J Bone Miner Res (1996) 1.54
Gender-specific relationship between serum free and total IGF-I and bone mineral density in elderly men and women. Eur J Endocrinol (1998) 1.51
Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res (1998) 1.51
Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support. J Natl Cancer Inst (1996) 1.49
Intracellular forms of adenovirus DNA. 3. Integration of the DNA of adenovirus type 2 into host DNA in productively infected cells. J Virol (1974) 1.48
Minimally invasive surgery for solitary parathyroid adenomas in patients with primary hyperparathyroidism: role of US with supplemental CT. Radiology (2001) 1.47
Utility assessment in cancer patients: adjustment of time tradeoff scores for the utility of life years and comparison with standard gamble scores. Med Decis Making (1994) 1.46
Are changes in sexual functioning during midlife due to aging or menopause? Fertil Steril (2001) 1.44
Peripheral neurotoxicity induced by docetaxel. Neurology (1996) 1.42
Regulation of cytolytic activity in CD3- and CD3+ killer cell clones by monoclonal antibodies (anti-CD16, anti-CD2, anti-CD3) depends on subclass specificity of target cell IgG-FcR. J Immunol (1987) 1.40
[How can the results of primary-care treatment for depression be improved?]. Tijdschr Psychiatr (2007) 1.39
Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response. J Clin Oncol (1993) 1.39
Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. J Clin Invest (2001) 1.38
Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer (2001) 1.37
Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas (1995) 1.37
Oral discomfort at menopause. Oral Surg Oral Med Oral Pathol (1989) 1.34
Estrogen - a potential treatment for schizophrenia. Schizophr Res (2001) 1.34
Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer (2003) 1.32
Menopausal symptoms in Australian women. Med J Aust (1993) 1.32
Characterization of a human multilineage-colony-stimulating factor cDNA clone identified by a conserved noncoding sequence in mouse interleukin-3. Gene (1987) 1.30
Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sci U S A (1995) 1.25
The treatment-seeking woman at menopause. Maturitas (1994) 1.25
Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer (1996) 1.24
Hip geometry, bone mineral distribution, and bone strength in European men and women: the EPOS study. Bone (2000) 1.23
Quantitation of human immunodeficiency virus type 1 during pregnancy: relationship of viral titer to mother-to-child transmission and stability of viral load. Proc Natl Acad Sci U S A (1994) 1.22
Intracellular forms of adenovirus DNA: integrated form of adenovirus DNA appears early in productive infection. Proc Natl Acad Sci U S A (1976) 1.22
Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer (2003) 1.22
Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained. J Clin Oncol (1996) 1.21
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer (2003) 1.21
Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecol Oncol (1988) 1.19
Human immunodeficiency virus type 1 expression in the central nervous system correlates directly with extent of disease. Proc Natl Acad Sci U S A (1990) 1.19
Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group. Br J Cancer (1996) 1.17
Quantification of apoptotic cells with fluorescein isothiocyanate-labeled annexin V in chinese hamster ovary cell cultures treated with cisplatin. Cytometry (1996) 1.16
The spliceosome as target for anticancer treatment. Br J Cancer (2008) 1.15
Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst (1995) 1.15
Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukaemia. Br J Haematol (1990) 1.15
Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. Br J Cancer (2002) 1.15
Hyperinsulinemia and bone mineral density in an elderly population: The Rotterdam Study. Bone (1996) 1.14
Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychol Med (2004) 1.12
Vitamin D receptor genotype is associated with radiographic osteoarthritis at the knee. J Clin Invest (1997) 1.12
Transmission of lymphadenopathy-associated virus/human T lymphotropic virus type III in sexual partners. Seropositivity does not predict infectivity in all cases. Am J Med (1986) 1.11
Patterns of chromosomal imbalances in muscle invasive bladder cancer. Int J Oncol (2000) 1.10
Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res (1995) 1.10
Age related changes in follicle stimulating hormone, luteinizing hormone, oestradiol and immunoreactive inhibin in women of reproductive age. Clin Endocrinol (Oxf) (1992) 1.09
Sexuality, hormones and the menopausal transition. Maturitas (1997) 1.09
Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines. Int J Cancer (1997) 1.09
Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract (1996) 1.09
Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer (2001) 1.08
Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol (2001) 1.08
Effects of a venous cuff at the venous anastomosis of polytetrafluoroethylene grafts for hemodialysis vascular access. J Vasc Surg (2000) 1.08
Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09. J Natl Cancer Inst (1994) 1.07
Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res (1998) 1.05
Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study. BMJ (1996) 1.05
Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. Leukemia (1994) 1.05
The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer (1997) 1.05
Mood and the menopausal transition. J Nerv Ment Dis (1999) 1.03
Integration of adenovirus DNA into the cellular genome. Cold Spring Harb Symp Quant Biol (1975) 1.03
Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours. Br J Cancer (1993) 1.03
Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl (1997) 1.02
PCR-mediated recombination: a general method applied to construct chimeric infectious molecular clones of plasma-derived HIV-1 RNA. Nat Med (1999) 1.02
SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line. Cancer Res (2001) 1.02